Clinical Trials

Clinical Trial Detail

Return to search results.

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

Complete title: Cellular Proliferation Imaging Using [18F]fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors

Research Study Number       7754
    
Principal Investigator       Jason Rockhill
    
Phase       NA

Look up trial at NIH

Research Study Description

This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with brain tumors. Comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Have a diagnosis of malignant brain tumor (primary, recurrent, or metastatic) by standard clinical-pathological diagnosis

- Planned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combined

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Inability to provide informed consent

- Pregnancy

- Inability to lie still for the imaging study

- Weight over 350 lbs.

Other exclusion criteria may apply.



Research Study Number       7754
    
Contact       Kristin Kauno
    
Telephone       206/598-7883
    
   

Keywords
Brain Cancer; Central Nervous System (CNS); Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials